ADAR1 Capital Management logo

ADAR1 Capital Management

Description

ADAR1 Capital Management is an investment firm.

Investor Profile

ADAR1 Capital Management has backed more than 10 startups, with 8 new investments in the last 12 months alone. The firm has led 0 rounds, about 0% of its total and boasts 6 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Post Ipo Equity, Series C, Series A rounds (top funding stages).
  • Majority of deals are located in United States.
  • Strong thematic focus on Biotechnology, Health Care, Therapeutics.

Stage Focus

  • Post Ipo Equity (80%)
  • Series C (10%)
  • Series A (10%)

Country Focus

  • United States (100%)

Industry Focus

  • Biotechnology
  • Health Care
  • Therapeutics
  • Life Science
  • Medical
  • Pharmaceutical
  • Genetics
  • Robotics
  • Health Diagnostics
  • Biopharma
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does ADAR1 Capital Management frequently co-invest with?

BP
North America, California, United States, San Francisco
Co-Investments: 1
Nantahala Capital Management
North America, Connecticut, United States, New Canaan
Co-Investments: 3
Venrock Healthcare Capital Partners
North America, California, United States, Palo Alto
Co-Investments: 1
Co-Investments: 1
Frazier Life Sciences
North America, California, United States, Menlo Park
Co-Investments: 2
RA Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 3
VC
North America, Georgia, United States, Alpharetta
Co-Investments: 1
SC
North America, Oregon, United States, Bend
Co-Investments: 2
Co-Investments: 2
Janus Henderson Investors
Europe, England, United Kingdom, London
Co-Investments: 4

What are some of recent deals done by ADAR1 Capital Management?

OnKure Therapeutics

Boulder, Colorado, United States

OnKure is a clinical-stage biopharma company developing precision medicines targeting validated cancer drivers.

BiotechnologyLife SciencePrecision MedicineTherapeutics
Post Ipo EquityMar 27, 2026
Amount Raised: $150,000,000
Diamyd Medical

Stockholm, Stockholms Lan, Sweden

Diamyd Medical is a Swedish diabetes company active in the field of pharmaceutical development.

BiotechnologyHealth DiagnosticsMedical Device
Post Ipo EquityMar 23, 2026
Amount Raised: $24,864,255
Ovid Therapeutics

New York, New York, United States

Ovid Therapeutic's purpose is to solve intractable medical problems.

BiopharmaBiotechnologyHealth Care
Post Ipo EquityMar 17, 2026
Amount Raised: $60,000,000
Acumen Pharmaceuticals

Carmel, Indiana, United States

Acumen is developing targeted therapies for the safe and effective treatment of Alzheimer’s Disease and related neurodegenerative diseases.

BiotechnologyHealth DiagnosticsTherapeutics
Post Ipo EquityMar 16, 2026
Amount Raised: $35,750,000
Korro Bio

Cambridge, Massachusetts, United States

Korro Bio provides an efficient and selective method for RNA editing, leveraging natural processes common to all multi-cellular organisms.

BiotechnologyHealth CarePharmaceutical
Post Ipo EquityMar 9, 2026
Amount Raised: $85,000,000
Athira Pharma

Seattle, Washington, United States

Athira Pharma is a clinical stage drug development company that specializes in biotechnology and pharmaceutical.

BiotechnologyPharmaceuticalTherapeutics
Post Ipo EquityDec 18, 2025
Amount Raised: $90,000,000
Kalaris Therapeutics

Houston, Texas, United States

Kalaris Therapeutics is a biopharmaceutical company that provides development and commercialization of treatments for retinal diseases.

BiotechnologyClinical TrialsPharmaceutical
Post Ipo EquityDec 17, 2025
Amount Raised: $50,000,000
Crescent Biopharma

Rockville, Maryland, United States

Crescent Biopharma is a biotechnology firm focused on developing novel precision-engineered medicines.

BiotechnologyHealth CareMedical Device
Post Ipo EquityDec 4, 2025
Amount Raised: $185,000,000
Kazia Therapeutics

Hornsby, New South Wales, Australia

Kazia Therapeutics is an oncology focused biotechnology company.

BiotechnologyClinical TrialsCommercialInnovation ManagementOncologyPharmaceutical
Post Ipo EquityDec 2, 2025
Amount Raised: $32,874,190
Bambusa Therapeutics

Boston, Massachusetts, United States

Bambusa Therapeutics operates as biotechnology company.

BiotechnologyHealth CareLife ScienceMedical
Series ANov 17, 2025

Find More Investors Like ADAR1 Capital Management

Discover similar investors in our database and build your perfect investor list.

Need help with your fundraising strategy?Read our fundraising guides

ADAR1 Capital Management | Pipeseed